CLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL)

2025-520790-39-00 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 4 Mar 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 7
Countries 1
Sites 1

relapsed or refractory AL amyloidosis

Key facts

Sponsor
Universitaetsklinikum Heidelberg AöR
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
4 Mar 2026 → ongoing
Decision date (initial)
2025-11-25
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

relapsed or refractory AL amyloidosis

VersionLevelCodeTermSystem organ class
23.0 LLT 10083938 Amyloid light-chain amyloidosis 10021428

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Heidelberg AöR

Sponsor organisation
Universitaetsklinikum Heidelberg AöR
Address
Im Neuenheimer Feld 672, Neuenheim Neuenheim
City
Heidelberg
Postcode
69120
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Heidelberg AöR
Contact name
Prof. Dr. med. Stefan Schönland

Public contact point

Organisation
Universitaetsklinikum Heidelberg AöR
Contact name
Prof. Dr. med. Stefan Schönland

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 7 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
Universitaetsklinikum Heidelberg AöR
Department of Internal Medicine V, Im Neuenheimer Feld 410, Neuenheim, Heidelberg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-03-04 2026-03-25

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-12 Germany Acceptable
2025-11-24
2025-11-25